PROCEPT BioRobotics (NASDAQ:PRCT) Director Antal Rohit Desai Purchases 160,317 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai bought 160,317 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $23.59 per share, for a total transaction of $3,781,878.03. Following the completion of the purchase, the director directly owned 327,563 shares of the company’s stock, valued at $7,727,211.17. The trade was a 95.86% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Antal Rohit Desai also recently made the following trade(s):

• On Monday, March 9th, Antal Rohit Desai purchased 98,699 shares of PROCEPT BioRobotics stock. The shares were acquired at an average price of $24.55 per share, for a total transaction of $2,423,060.45.
• On Thursday, March 5th, Antal Rohit Desai purchased 167,246 shares of PROCEPT BioRobotics stock. The shares were acquired at an average cost of $25.58 per share, with a total value of $4,278,152.68.

PROCEPT BioRobotics Trading Up 4.3%

NASDAQ PRCT opened at $25.26 on Tuesday. The stock has a market cap of $1.42 billion, a P/E ratio of -14.77 and a beta of 1.03. PROCEPT BioRobotics Corporation has a fifty-two week low of $19.35 and a fifty-two week high of $66.85. The stock has a 50 day simple moving average of $29.11 and a two-hundred day simple moving average of $32.83. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The business had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. PROCEPT BioRobotics’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted ($0.35) earnings per share. On average, analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds have recently modified their holdings of PRCT. Prosight Management LP boosted its stake in PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after acquiring an additional 1,303,009 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the last quarter. Chicago Capital LLC lifted its holdings in shares of PROCEPT BioRobotics by 175.7% during the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after purchasing an additional 999,873 shares during the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in shares of PROCEPT BioRobotics by 113.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock worth $92,065,000 after purchasing an additional 849,792 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Analyst Ratings Changes

PRCT has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. UBS Group started coverage on shares of PROCEPT BioRobotics in a research note on Friday, December 12th. They set a “buy” rating and a $62.00 target price on the stock. Piper Sandler reduced their price target on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, TD Cowen lowered their price objective on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.82.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.